DESCRIPTION
| CONTRAINDICATIONS AND
WARNINGS
PREGNANCY MUST BE EXCLUDED BEFORE THE START
OF TREATMENT WITH ARAVA. ARAVA IS CONTRAINDICATED
IN PREGNANT WOMEN OR WOMEN OF CHILDBEARING POTENTIAL
WHO ARE NOT USING RELIABLE CONTRACEPTION (SEE CONTRAINDICATIONS
AND WARNINGS.) PREGNANCY MUST BE AVOIDED DURING
ARAVA TREATMENT OR PRIOR TO THE COMPLETION OF THE
DRUG ELIMINATION PROCEDURE AFTER ARAVA TREATMENT.
|
ARAVA™ (leflunomide) is a pyrimidine synthesis
inhibitor The chemical name for leflunomide is N-(4'-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide
It has an empirical formula C12H9F3N2O2, a molecular weight
of 270.2.
ARAVA is available for oral administration as tablets
containing 10, 20 or 100 mg of active drug. Combined with
leflunomide are the following inactive ingredients: colloidal
silicon dioxide, crospovidone hydroxylpropyl methylcellulose,
lactose monohydrate, magnesium stearate, polyethylene
glycol, povidone, starch, talc, titanium dioxide, and
yellow ferric oxide (20 mg tablet only).
| 
